Scientific publication in Medical Biology – Tumor Hypoxia and metabolism Team


L’équipe de recherche du CSM "Hypoxie tumorale et Métabolisme". De gauche à droite : Dr M. Vucetic, M. P-A. Massard, Dr J. Pouysségur, Dr Y. Cormerais et Dr S. Parks. Ces recherches présentées par le Dr Y. Cormerais (post-doct Harvard), ont été financées par le Centre Scientifique de Monaco et une subvention du GEMLUC. © CSM

We validated that the ASCT2 glutamine transporter, like LAT1 essential amino acid transporter, are anti-cancer targets. We also revised the generally accepted ASCT2 / LAT1 functional coupling model.
 

The CSM "Tumor Hypoxia and Metabolism" team is investigating the nutritional and oxidative stress of rapidly growing cancer cells (depletion of oxygen and nutrients in tumors). Glucose and amino acids required for energy and growth can only cross cell membranes through transport systems. Of the twenty or so amino acid transporters (AAs), two, including the LAT1 / CD98 complex facilitating the entry of essential AA, and ASCT2 carrying glutamine are overexpressed in a variety of cancers suggestive of 'Darwinian selection' offering a nutritional advantage to tumors. After demonstrating that the LAT1 transporter is an anti-cancer target (Cancer Res, 2016), we explored the ASCT2 glutamine transporter and revisited the LAT1 / ASCT2 functional coupling model generally accepted in the scientific community. We demonstrate by the CRISPR-Cas9 invalidation technique of the ASCT2 gene:

  1. that the import of glutamine via ASCT2 is crucial for tumor growth (colon, lung),
  2. that this action is independent of the functional coupling LAT1 / ASCT2.​​​​​​​
This article was published in the American journal "Journal of Biological Chemistry" an international reference in Biological Chemistry.
 
 

For more information, please contact :